Selected as an enterprise with excellent technology by NICE Information Service

Established internal accounting systems

Terminated phase 1/2a clinical trial for administration of
chronic interstitial cystitis (Asan Medical Center)

Registered a patent for MMSC original technology (China) 类似间充质干细胞的制备方法

Singed an MOU on the revitalization of the Jeju biotechnology industry

Completed toxicity tests for MMSC conditioned medium

Won the project of Ministry of Agriculture, Food and Rural Affairs’ technology commercialization
support project (2 years, 8 months; KRW 740 million)

Joined the Korea Pharmaceutical and Bio-Pharma Manufacturers Association

Published paper on phase 1b clinical trials (Stem Cells Transl Med.2022 Oct; 11(10):1010-1020)

Obtained approval for phase 1/2a underactive bladder clinical trial plans (No. 101095)

MMSC production technology certified as New Excellent Technology (NET) (No. 197)

Launched stem cell conditioned medium cosmetic brand Stemelin on GS SHOP

Joined the Korea Biotechnology Industry Organization

Applied a patent for preventing pluripotent stem cell-based muscle inflammation or
muscular disorders accompanying inflammation

Applied a patent for preventing pluripotent stem cell-based vasogenic cognitive disorders and dementia

Obtained approval as advanced pharmaceutical company (No. 34)

Registered a patent for MMSC original technology (Japan)
類似間葉系幹細胞の製造方法及びこれにより製造された類似間葉系幹細胞

Transferred the original technology for commercialization of dementia treatment technology

Won the Korean Fund for Regenerative Medicine for acute ischemic strokes
(3 years, 8 months; KRW 590 million)

Launched Black Pla, a Jeju black cattle placenta cosmetic brand

Registered a patent for MMSC original technology (Australia)
Method of Preparing Mesenchymal-Like Stem Cells and Mesenchymal-Like Stem Cells Prepared Thereby

World’s first to register MMSC conditioned medium

Registered a patent for porcine Thy-1 gene promoter specifically expressed in neurons (US)

Won the project of Korean Fund for Regenerative Medicine for phase 1/2a chronic interstitial cystitis
(2 years, 8 months; KRW 2.34 billion)

Registered a patent for compositions for treatment or prevention of pluripotent stem cell-based
autoimmune and inflammatory skin disorders and the manufacturing methods thereof

Signed an MOU on the industrial growth of Jeollanam-do cutting-edge regenerative treatments
[Mirae Cell Bio: Jeonnam Bio Foundation Biopharmaceutical Research Center]

Developed the world’s first stem cell treatment body tracking technology

Registered a patent for the method of manufacturing mesenchymal-like stem cells
and the manufactured mesenchymal-like stem cells

Designated as chronic interstitial cystitis development stage orphan drug (No. 30)

Obtained approval for phase 1/2a chronic interstitial cystitis commercialization clinical trial plans (No. 33308)

Obtained approval for chronic interstitial cystitis research and clinical trial plans (No. 32855)

Acquired ISO 9001:2015 and ISO 14001:2015 certifications

Attracted KRW 10 billion in institutional investment

Registered a patent for stem cell treatment for revascularization or prevention
of vascular injury including new improved functionality mesenchymal stem cells
and the manufacturing method thereof

Registered a patent for division and culture methods for living cells of long-extinct or fossilized life

Registered a patent for non-antibiotic, serum-free mesenchymal stem cell conditioned media,
the manufacturing method thereof, and related cosmetic compositions

Registered a patent for expression cassette and vector comprising Alzheimer’s disease-related
mutant genes and cell line transformed by means of same (abroad)

Registered a patent for specific manifestation of nerve cell porcine Thy-1 gene promoter

Won the project of developing new biopharmaceuticals derived from Jeollanam-do stem cells
(3 years; KRW 790 million)

Registered a patent for stem cell anti-inflammatory treatment including new improved
functionality mesenchymal stem cells and manufacturing method for mesenchymal precursor cells

Registered as Ministry of Health and Welfare Embryo Research Institution No. 68

Established Seongsu GMP

Registered a patent for expression cassette and vector comprising Alzheimer’s disease-related
mutant genes and cell line transformed by means of same (Korea)

Won the project of developing brand differentiation strategy for Jeju black cattle and of industrial technology
(7 years; KRW 2.59 billion)

Registered a patent for the method of manufacturing stem cells with versatility derived from human stem cells

Launched stem cell conditioned medium cosmetics

Inaugurated co-CEOs Kim Eun-young and Chung Hyung-min
Changed company name to Mirae Cell Bio

Won the Next-generation Bio Green 21 Project of developing production
technology for transformative cloning center

Participated in the Woo Jang-choon Project for development of Alzheimer’s
model for porcine (5 years; KRW 6 billion)

Registered a patent for skin cell regeneration compositions, skin cell regeneration methods,
and cosmetic compositions

Registered a patent for the method of manufacturing embryonic stem cells with
genetic introduction using nanoparticles

Launched stem cell conditioned medium cosmetics

Won the IPET’s project of developing mass proliferation technology for Jeju black cattle

Acquired venture company certification

Established the Mirae Biotechnology Research Center Inaugurated CEO Park Se-pill